Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario

Abstract

Locally advanced breast cancer (LABC) forms a significant proportion of the total breast cancer (BC) burden in the country. It is a heterogeneous entity, encompassing a variety of presentations indicative of advanced disease. The standard of care for the treatment of LABC is multimodal, involving chemotherapy, surgery, radiation, and/or hormonal therapy. With improved understanding of the biology of BC, addition of newer agents of systemic therapy to our armamentarium, advances in surgical techniques and radiation delivery, clinicians are now able to tailor treatment according to the individual and consider a more conservative approach to management (in contrast to a mandatory radical mastectomy, decades ago), disease biology, and stage permitting with better survival outcomes. Here, we review all the treatment modalities and options available to aid a clinician in formulating an optimal treatment plan for a patient presenting with LABC and also how best to tailor the treatment to enable cost effectiveness in the Indian setting.

Keywords

locally advanced breast cancer - neoadjuvant systemic therapy - breast conservation in LABC - cost effectiveness - multimodal management

Publication History

Article published online:
06 August 2021

• References

• 1 International Agency for Research on Cancer; World Health Organization. Brest. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. Accessed December 29, 2020
• 2 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
• 3 Agarwal G, Ramakant P. Breast cancer care in India: the current scenario and the challenges for the future. Breast Care Basel 2008; 3 (01) 21-27
• 4 Amim MB, Edge SG, Greene F. et al. eds. AJCC Cancer Staging Manual. Switzerland: Springer 2017
• 5 Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10 (06) 1014-1024
• 6 Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005; 7 (02) 52-58
• 7 Gradishar W, Moran M, Abraham J, et al. 2021. NCCN Guidelines® Insights: Breast Cancer, Version 4.2021: Featured Updates to the NCCN Guidelines. [online] JNCCN. Available at: <https://jnccn.org/view/journals/jnccn/19/5/article-p484.xml> [Accessed 7 July 2021].
• 8 Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995; 4 (04) 715-734
• 9 Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332 (14) 901-906
• 10 Peto R, Davies C, Godwin J. et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012; 379 (9814) 432-444
• 11 Moore HCF, Unger JM, Phillips K-A. et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst 2019; 111 (02) 210-213
• 12 Rastogi P, Anderson SJ, Bear HD. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26 (05) 778-785
• 13 Citron ML, Berry DA, Cirrincione C. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21 (08) 1431-1439
• 14 Hussain N, Said AS, Khan Z. Safety assessment of neoadjuvant pertuzumab combined with trastuzumab in nonmetastatic HER2-positive breast cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer 2018; 2018: 6106041
• 15 Slamon D, Eiermann W, Robert N. et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365 (14) 1273-1283
• 16 von Minckwitz G, Huang C-S, Mano MS. et al. KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380 (07) 617-628
• 17 Masuda N, Lee S-J, Ohtani S. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376 (22) 2147-2159
• 18 Spring LM, Gupta A, Reynolds KL. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2 (11) 1477-1486
• 19 Halsted WS. I. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 1894; 20 (05) 497-555
• 20 McWHIRTER R. The value of simple mastectomy and radiotherapy in the treatment of cancer of the breast. Br J Radiol 1948; 21 (252) 599-610
• 21 Fisher B. Laboratory and clinical research in breast cancer–a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980; 40 (11) 3863-3874
• 22 Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347 (08) 567-575
• 23 Fisher B, Anderson S, Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347 (16) 1233-1241
• 24 Veronesi U, Cascinelli N, Mariani L. et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347 (16) 1227-1232
• 25 Veronesi U, Bonadonna G, Zurrida S. et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 1995; 222 (05) 612-618
• 26 Scholl SM, Fourquet A, Asselain B. et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A [phone]
• 27 Mauriac L, MacGrogan G, Avril A. et al. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol 1999; 10 (01) 47-52
• 28 Parmar V, Krishnamurthy A, Hawaldar R. et al. Breast conservation treatment in women with locally advanced breast cancer - experience from a single centre. Int J Surg 2006; 4 (02) 106-114
• 29 Chen AM, Meric-Bernstam F, Hunt KK. et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 2004; 22 (12) 2303-2312
• 30 Zhou X, Li Y. Local recurrence after breast-conserving surgery and mastectomy following neoadjuvant chemotherapy for locally advanced breast cancer - a meta-analysis. Breast Care Basel 2016; 11 (05) 345-351
• 31 Mamounas EP, Anderson SJ, Dignam JJ. et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012; 30 (32) 3960-3966
• 32 Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 2014; 21 (03) 717-730
• 33 Silverstein MJ, Savalia N, Khan S, Ryan J. Extreme oncoplasty: breast conservation for patients who need mastectomy. Breast J 2015; 21 (01) 52-59
• 34 Koppiker CB, Noor AU, Dixit S. et al. Extreme oncoplastic surgery for multifocal/multicentric and locally advanced breast cancer. Int J Breast Cancer 2019; 2019: 4262589
• 35 Veronesi U, Cascinelli N, Bufalino R. et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 1983; 198 (06) 681-684
• 36 Handley RS, Thackray AC. Invasion of internal mammary lymph nodes in carcinoma of the breast. BMJ 1954; 1 (4853) 61-63
• 37 Urban JA. Extended radical mastectomy for breast cancer. Am J Surg 1963; 106: 399-404
• 38 Lacour J, Bucalossi P, Cacers E. et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Five-year results of an international cooperative study. Cancer 1976; 37 (01) 206-214
• 39 Sugarbaker ED. Extended radical mastectomy: its superiority in the treatment of breast cancer. JAMA 1964; 187 (02) 96-99
• 40 Veronesi U, Valagussa P. Inefficacy of internal mammary nodes dissection in breast cancer surgery. Cancer 1981; 47 (01) 170-175
• 41 Overgaard M, Hansen PS, Overgaard J. et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997; 337 (14) 949-955
• 42 Overgaard M, Jensen MB, Overgaard J. et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999; 353 (91/65) 1641-1648
• 43 Ragaz J, Olivotto IA, Spinelli JJ. et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005; 97 (02) 116-126
• 44 Clarke M, Collins R, Darby S. et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366 (9503) 2087-2106
• 45 Recht A, Comen EA, Fine RE. et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline update. Pract Radiat Oncol 2016; 6 (06) e219-e234
• 46 McGuire SE, Gonzalez-Angulo AM, Huang EH. et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007; 68 (04) 1004-1009
• 47 Bentzen SM, Agrawal RK, Aird EG. et al. START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008; 9 (04) 331-341
• 48 Bentzen SM, Agrawal RK, Aird EG. et al. START Trialists’ Group. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 2008; 371 (96/18) 1098-1107
• 49 Budach W, Kammers K, Boelke E, Matuschek C. Adjuvant radiotherapy of regional lymph nodes in breast cancer - a meta-analysis of randomized trials. Radiat Oncol 2013; 8: 267
• 50 Mamounas EP, Bandos H, Lembersky BC. et al. A randomized trial of five years of letrozole versus placebo after aromatase inhibitor-based therapy: NRG Oncology/NSABP B-42. Lancet Oncol 2019; 20 (01) 88-99
• 51 Davies C, Pan H, Godwin J. et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381 (98/69) 805-816
• 52 Gray RG, Rea D, Handley K. et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. JCO 2013; 31 (18) 5-5
• 53 Francis PA, Regan MM, Fleming GF. et al. SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372 (05) 436-446
• 54 Pagani O, Regan MM, Walley BA. et al. TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371 (02) 107-118
• 55 Gnant M, Pfeiler G, Steger GG. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20 (03) 339-351
• 56 Gnant M, Pfeiler G, Dubsky PC. et al. Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386 (9992) 433-443
• 57 Khatcheressian JL, Wolff AC, Smith TJ. et al. American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 2006; 24 (31) 5091-5097
• 58 Okonkwo QL, Draisma G, der Kinderen A, Brown ML, de Koning HJ. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India. J Natl Cancer Inst 2008; 100 (18) 1290-1300
• 59 Mittra I, Mishra GA, Dikshit RP. et al. Effect of screening by clinical breast examination on breast cancer incidence and mortality after 20 years: prospective, cluster randomised controlled trial in Mumbai. BMJ 2021; 372: n256
• 60 Joensuu H, Kellokumpu-Lehtinen P-L, Bono P. et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354 (08) 809-820
• 61 Barbier L, Declerck P, Simoens S, Neven P, Vulto AG, Huys I. The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. Br J Cancer 2019; 121 (03) 199-210
• 62 Nelson KM, Gallagher PC. Biosimilars lining up to compete with Herceptin–opportunity knocks. Expert Opin Ther Pat 2014; 24 (11) 1149-1153
• 63 Iyer P, Radhakrishnan V, Balasubramanian A. et al. Study of pathological complete response rate with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer. Indian J Cancer 2020; 57 (04) 428-434
• 64 Adams S, Chakravarthy AB, Donach M. et al. Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival. Breast Cancer Res Treat 2010; 124 (03) 723-732